C4 Therapeutics Inc (CCCC) Stock Price, Quote & News

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BR...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 231 0700

Website: www.c4therapeutics.com

Address:

490 Arsenal Way, Suite120, Watertown, United States

StevePattersonTrading Feb. 25 at 12:26 AM

Busy day all my closed trades 43% profits on risk today. I thought $IOVA might tank afterhours but it didnt. $RIME $CCCC $CDIO $ANPA

0 · Reply

GrizZley Feb. 24 at 9:14 PM

$CCCC $GERN $SLS SLS for the win. Cancer cure in the making.

0 · Reply

IBBullish Feb. 24 at 8:30 PM

$CCCC sell the news today

1 · Reply

JuggernautRaider Feb. 24 at 7:49 PM

$CCCC $GERN $SLS all look like major winners in the blood cancer space… it’s not too late! ⏰

0 · Reply

PennySearch Feb. 24 at 7:30 PM

$NXL - 5.36x RVOL +17% 2.8M volume (515.0K avg) $10.7M market cap Day Range: 0.50 – 0.65 52W Range: 0.37 – 3.03 $CCCC - 3.55x RVOL +5% 5.3M volume (1.5M avg) $172.6M market cap Day Range: 2.34 – 2.77 52W Range: 1.08 – 3.65 $CRBU - 2.79x RVOL +14% 3.7M volume (1.3M avg) $206.2M market cap Day Range: 1.87 – 2.22 52W Range: 0.66 – 3.54 Top gainers with unusually high relative volume. Momentum + attention in one screen. Which one are you watching? 👀 PennySearch

0 · Reply

Andysss Feb. 24 at 6:57 PM

$CCCC insane volatility. momentum traders taking profit and shorts leaning into strength m. Volume elevated, but price action suggests rotation. Thoughts?

0 · Reply

Nit2WinIt27 Feb. 24 at 4:34 PM

$CCCC Any idea what earnings report on the 26th will do to this stock?

0 · Reply

_Sasuke3x Feb. 24 at 4:31 PM

Caught a few of @TheMorningStew alerts over the last few weeks that went crazy! Give him a follow 🔥 $CCCC $LEGN $BROS $TARA

0 · Reply

StevePattersonTrading Feb. 24 at 4:08 PM

My open shorts today $CCCC $RIME $ANPA $CDIO

1 · Reply

Profitrip Feb. 24 at 3:51 PM

$CCCC pull back $2.5> 9ema on 15 min

0 · Reply

C4 Therapeutics to Participate in Upcoming March Conferences

$C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma$

Feb 23, 2026, 7:00 AM EST - 1 day ago

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Feb 9, 2026, 4:01 PM EST - 15 days ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 4, 2026, 7:00 AM EST - 20 days ago

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 14, 2026, 7:00 AM EST - 5 weeks ago

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

Nov 26, 2025, 6:27 AM EST - 3 months ago

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss

Nov 25, 2025, 7:00 AM EST - 3 months ago

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 10:16 AM EST - 3 months ago

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

CWST ESPR INSP MNDY SITM

Nov 6, 2025, 7:00 AM EST - 3 months ago

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 16, 2025, 7:08 AM EDT - 4 months ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

$C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma$

Oct 1, 2025, 7:00 AM EDT - 5 months ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Sep 22, 2025, 5:23 AM EDT - 5 months ago

C4 Therapeutics, Inc. - Special Call

Sep 20, 2025, 11:00 AM EDT - 5 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Sep 4, 2025, 7:00 AM EDT - 6 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 3, 2025, 7:00 AM EDT - 6 months ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Aug 7, 2025, 7:00 AM EDT - 7 months ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 16, 2025, 1:50 PM EDT - 9 months ago

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

May 7, 2025, 7:00 AM EDT - 10 months ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 24, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Dec 8, 2024, 12:30 PM EST - 1 year ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Sep 13, 2024, 10:00 AM EDT - 1 year ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 3, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Aug 29, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 16, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jun 10, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

May 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 9, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 8, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Jan 9, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 4, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

$C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma$

Dec 12, 2023, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

$C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma$

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 1, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Oct 11, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces Chief Financial Officer Succession

Aug 8, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 15, 2023, 1:58 AM EDT - 2 years ago

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

StevePattersonTrading Feb. 25 at 12:26 AM

Busy day all my closed trades 43% profits on risk today. I thought $IOVA might tank afterhours but it didnt. $RIME $CCCC $CDIO $ANPA

0 · Reply

GrizZley Feb. 24 at 9:14 PM

$CCCC $GERN $SLS SLS for the win. Cancer cure in the making.

0 · Reply

IBBullish Feb. 24 at 8:30 PM

$CCCC sell the news today

1 · Reply

JuggernautRaider Feb. 24 at 7:49 PM

$CCCC $GERN $SLS all look like major winners in the blood cancer space… it’s not too late! ⏰

0 · Reply

PennySearch Feb. 24 at 7:30 PM

0 · Reply

Andysss Feb. 24 at 6:57 PM

$CCCC insane volatility. momentum traders taking profit and shorts leaning into strength m. Volume elevated, but price action suggests rotation. Thoughts?

0 · Reply

Nit2WinIt27 Feb. 24 at 4:34 PM

$CCCC Any idea what earnings report on the 26th will do to this stock?

0 · Reply

_Sasuke3x Feb. 24 at 4:31 PM

Caught a few of @TheMorningStew alerts over the last few weeks that went crazy! Give him a follow 🔥 $CCCC $LEGN $BROS $TARA

0 · Reply

StevePattersonTrading Feb. 24 at 4:08 PM

My open shorts today $CCCC $RIME $ANPA $CDIO

1 · Reply

Profitrip Feb. 24 at 3:51 PM

$CCCC pull back $2.5> 9ema on 15 min

0 · Reply

BioRich Feb. 24 at 3:33 PM

$CCCC Nice movement this morning showing what this beauty is capable of. Trial and platform progression with a massive PT improvement from Brookline will bring this A LOT of attention. Sharing to $XBI for broader exposure for this impressive opportunity. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. Let's make some (more) money. Cheers!

0 · Reply

JuggernautRaider Feb. 24 at 3:07 PM

$CCCC $SLS two potential best-in-class blood cancer biotechs 💪

0 · Reply

AnomalyDetective Feb. 24 at 2:59 PM

$CCCC +25.4% the 2nd of four Week 9 MDA breakout picks for members up over 10% in less than a week with $SLS +15.6% still going strong through Tuesday despite high negative #SPX S&P 500 Momentum Gauges signals from January. Continue with caution as traders tend to sell aggressively in negative market signals and use the http://vmbreakouts.com signals for the best results. Credit: @vmbreakouts

0 · Reply

NathDrake Feb. 24 at 2:54 PM

$CCCC So is this dead or no?

1 · Reply

SannieVerraderlijk Feb. 24 at 2:35 PM

$CCCC Lovely

0 · Reply

_Crocodile_Teeth Feb. 24 at 12:30 AM

Special thanks to @SqueezeSharkie for nailing that trade, He is worth Following for sure 💯 $VVPR $CCCC $CRBU $AAOI nice news

0 · Reply

StockProfitz Feb. 23 at 7:27 PM

$CCCC phase 2 trial happening

0 · Reply

erevnon Feb. 23 at 6:42 PM

Brookline Capital maintains C4 Therapeutics $CCCC at Buy and raises the price target from $20 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

zawojak Feb. 23 at 5:39 PM

$CCCC TP increased to $30

0 · Reply

BioTuesdays Feb. 23 at 2:38 PM

$CCCC has announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM). https://biotuesdays.com/2026/02/23/c4-doses-first-patient-in-phase-2-trial-of-cemsidomide-in-rrmm/

0 · Reply

SannieVerraderlijk Feb. 23 at 12:21 PM

$CCCC https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-announces-first-patient-dosed-phase-2-momentum

0 · Reply

Market Cap	222.90M
Revenue (ttm)	35.58M
Net Income (ttm)	-105.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-296.01%
Debt to Equity Ratio	0.00

Volume	6,072,700
Avg Vol	1,587,902
Day's Range	N/A - N/A
Shares Out	96.91M
Stochastic %K	63%
Beta	2.96
Analysts	Strong Sell
Price Target	$9.86